Society of Dermatology Physician Assistants (SDPA) Summer, 2024 

Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT

Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials